Although AML1G190R and AML1A297LfsX7 mutants found in our clinical samples co-operated with BCR-ABL to confer growth advantage upon cells in culture (Figure S12), we focused on AML1K83Q, AML1R80C and AML1R139G mutants for detailed analysis because these mutations recurrently occur in BC (Table S2). Here, ABL1 is linked to breast cancer.